Affimed

Affimed Intangible Assets

Delisted

The Intangible Assets of Affimed (AFMD) as of Nov 20, 2026 is 25,000.00 EUR. In the previous year, Intangible Assets was 58,000.00 EUR — a change of -56.90% (lower).

Intangible Assets

25,000.00EUR

YoY

-56.90%

Last updated:

Intangible Assets of Affimed is 2023 25,000.00 EUR. Intangible Assets of Affimed was 2022 58,000.00 EUR. It decreases by -56.90% lower compared to the previous year.

The Affimed Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2016
55,000.00 EUR
Jan 1, 2017
65,000.00 EUR
Jan 1, 2018
56,000.00 EUR
Jan 1, 2019
137,000.00 EUR
Jan 1, 2020
1.72 M EUR
Jan 1, 2021
1.61 M EUR
Jan 1, 2022
58,000.00 EUR
Jan 1, 2023
25,000.00 EUR
The Affimed Intangible Assets history
YEARIntangible AssetsYoY
25,000.00EUR-56.90%
58,000.00EUR-96.39%
1.61 MEUR-6.46%
1.72 MEUR+1,154.01%
137,000.00EUR+144.64%
56,000.00EUR-13.85%
65,000.00EUR+18.18%
55,000.00EUR-23.61%
72,000.00EUR0.00%
72,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Affimed Stock analysis

What does Affimed do? Affimed NV develops targeted cancer immunotherapies focused on immuno-oncology, leveraging the immune system to combat tumor cells. The company's product pipeline includes AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma, AFM13 combined with adoptive NK cells or anti-PD-1, and AFM24 for advanced EGFR-expressing solid tumors. Affimed is conducting a registration-directed study for AFM13 and a Phase 1/2a study for AFM24, alongside preclinical candidates like AMF26 for multiple myeloma and AMF28/AMF32 for multiple tumor targets. The firm collaborates with Genentech to develop and commercialize certain product candidates for multiple cancers. Affimed generates revenue primarily through collaboration agreements, such as the partnership with Genentech, which covers development and commercialization of specific therapies. The company's primary customers are pharmaceutical and biotechnology firms seeking to expand their oncology portfolios, particularly those interested in immuno-oncology approaches. Affimed's target segments include patients with relapsed/refractory peripheral T-cell Lymphoma, advanced EGFR-expressing solid tumors, and multiple myeloma, as well as broader oncology markets for its preclinical candidates. The company's revenue streams are tied to milestone payments and potential royalties from partnered products, with Genentech being a key collaborator. Affimed's focus on immuno-oncology positions it to attract partnerships with major pharmaceutical players looking to enhance their cancer therapy offerings. Its clinical-stage products, such as AFM13 and AFM24, are in advanced development phases, making them attractive for strategic alliances that drive commercialization and revenue generation. Affimed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Affimed stock

Intangible Assets of Affimed is 25,000.00 EUR in 2023.

Intangible Assets of Affimed changed from 58,000.00 EUR to 25,000.00 EUR, representing a -56.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Affimed since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Affimed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Affimed

All Key Metrics — Affimed